KR920701249A - Glycosylated insulin - Google Patents

Glycosylated insulin

Info

Publication number
KR920701249A
KR920701249A KR1019910701014A KR910701014A KR920701249A KR 920701249 A KR920701249 A KR 920701249A KR 1019910701014 A KR1019910701014 A KR 1019910701014A KR 910701014 A KR910701014 A KR 910701014A KR 920701249 A KR920701249 A KR 920701249A
Authority
KR
South Korea
Prior art keywords
insulin
glycosylated
glycosylated insulin
less
group
Prior art date
Application number
KR1019910701014A
Other languages
Korean (ko)
Inventor
브로베르크 할스트롬 요온
Original Assignee
안네 제케르
노보 노르디스크 아크티에 셀스카브
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안네 제케르, 노보 노르디스크 아크티에 셀스카브 filed Critical 안네 제케르
Publication of KR920701249A publication Critical patent/KR920701249A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음No content

Description

글리코실화 인슐린Glycosylated insulin

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (15)

하나 또는 둘 이상의 기 또는 셋이하의 설탕단위를 가진 하나 또는 둘 이상의 올리고당 기를 함유하고 있는 특정적으로 글리코실화된 인슐린.Particularly glycosylated insulin containing one or more oligosaccharide groups with one or more groups or less than three sugar units. 제1항에 있어서, 한단당기 또는 셋이하의 설탕단위를 가진 한 올리고당 기를 함유하고 있는 글리코실화인슐린.The glycosylated insulin according to claim 1, which contains one oligosaccharide group having a single sugar group or three sugar units or less. 제1항에 있어서, 두 단당기 또는 셋 이하의 설탕단위를 가진 두 올리고당 기를 함유하고 있는 글리코실화인슐린.The glycosylated insulin according to claim 1, which contains two oligosaccharide groups having two monosaccharide groups or less than three sugar units. 제1항에 있어서, 세단당기 또는 셋 이하의 설탕단위를 가진 세올리고당 기를 함유하고 있는 글리코실화인슐린.The glycosylated insulin according to claim 1, which contains a seoligosaccharide group having a sedan sugar group or three sugar units or less. 제2항에 있어서, 위치 A1, B1 또는 B29에서 모노클리코실화 되어 있는 글리코실화 인슐린.The glycosylated insulin of claim 2, which is monoclosylated at position A1, B1 or B29. 제3항에 있어서, 위치 A1과 B1;A1과 B29; 또는 B1과 B29에서 디글코실화 되어 있는 글리코실화 인슐린.The method of claim 3, further comprising: positions A1 and B1; A1 and B29; Or glycosylated insulin that is diglycosylated at B1 and B29. 제4항에 있어서, 위치 A1, B1 또는 B29에서 트리글리코실화 되어 있는 글리코실화 인슐린.The glycosylated insulin of claim 4 which is triglycosylated at positions A1, B1 or B29. 상기 항중의 어느 한 항에 있어서, 위치 B10에 Asp를 함유하는 글리코실화 인슐린.The glycosylated insulin of any one of the preceding clauses containing Asp at position B10. 상기 항중의 어느 한 항에 있어서, 모 인슐린종이 사람인 것을 특징으로 하는 글리코실화 인슐린.Glycosylated insulin according to any one of the preceding claims, wherein the parent insulin species is human. Phe(B1)글루코스 사람 인슐린.Phe (B1) glucose human insulin. Phe(B1), Gly(A1)디글루코스 사람 인슐린.Phe (B1), Gly (A1) diglucose human insulin. 상기 항들 중의 어느 한 항에 기재된 특정적 글리코실화 인슐린 적어도 90%, 바람직하게는 적어도 95%, 가장 바람직하게는 적어도 99%를 함유한 조성물.A composition containing at least 90%, preferably at least 95%, most preferably at least 99% of the specific glycosylated insulins described in any one of the preceding clauses. 선택적으로 제약적 허용 보조제와 첨가제 및 보존제와 병합된, 상기 항들 중의 어느 한 항에 기재된 특정적 글리코실화 인슐린 또는 그의 제약적 허용염을 함유하는 제약제제.A pharmaceutical formulation containing the specific glycosylated insulin or pharmaceutically acceptable salt thereof according to any one of the preceding clauses, optionally in combination with a pharmaceutically acceptable adjuvant and additives and preservatives. 수성 또는 유기매질 중에서 적절한 유리알데히드기를 가진 단당과 또는 유리알데히드기 및 3이하의 설탕 단위를 가진 올리고당과 반응시킨 뒤 소망하는 생성물을 반응 혼합물로 부터 분리하는, 상기 제1내지 11항중의 어느 한 항에 기재된 특정적 글리코실화 인슐린의 제조방법.The method according to any one of the preceding claims, wherein the desired product is separated from the reaction mixture by reacting with a monosaccharide having an appropriate free aldehyde group or an oligosaccharide having a free aldehyde group and a sugar unit of 3 or less in an aqueous or organic medium. A method of making specific glycosylated insulins as described. 명세서에 기재된 어떤 신규 특징(면모) 또는 특징(면모)들의 조합.Any novel feature (face) or combination of features (face) described in the specification. ※ 참고사항 : 최초출원 내용에 의하여 공개되는 것임.※ Note: This is to be disclosed by the original application.
KR1019910701014A 1989-03-08 1990-03-06 Glycosylated insulin KR920701249A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK111489A DK111489D0 (en) 1989-03-08 1989-03-08 PEPTIDES
DK1114/89 1989-03-08
PCT/DK1990/000062 WO1990010645A1 (en) 1989-03-08 1990-03-06 Glycosylated insulins

Publications (1)

Publication Number Publication Date
KR920701249A true KR920701249A (en) 1992-08-11

Family

ID=8101165

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910701014A KR920701249A (en) 1989-03-08 1990-03-06 Glycosylated insulin

Country Status (19)

Country Link
EP (1) EP0462192A1 (en)
JP (1) JPH04504117A (en)
KR (1) KR920701249A (en)
CN (1) CN1045586A (en)
AU (1) AU638701B2 (en)
CA (1) CA2049937A1 (en)
CS (1) CS114290A3 (en)
DD (1) DD296933A5 (en)
DK (1) DK111489D0 (en)
FI (1) FI914226A0 (en)
GR (1) GR1000604B (en)
HU (1) HUT59942A (en)
IL (1) IL93674A0 (en)
NO (1) NO913517L (en)
NZ (1) NZ232808A (en)
PT (1) PT93366A (en)
WO (1) WO1990010645A1 (en)
YU (1) YU45490A (en)
ZA (1) ZA901737B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE550041T1 (en) 2004-01-21 2012-04-15 Novo Nordisk Healthcare Ag TRANSGLUTAMINASE-MEDIATED CONJUGATION OF PEPTIDES
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
WO2010088268A1 (en) 2009-01-28 2010-08-05 Smartcells, Inc. Exogenously triggered controlled release materials and uses thereof
CN105753965A (en) 2009-01-28 2016-07-13 斯马特塞尔斯公司 Conjugate Based Systems For Controlled Drug Delivery
BRPI1007466A2 (en) 2009-01-28 2018-06-12 Smartcells Inc crystalline insulin conjugate, extended release formulation, and pump delivery system
US8569231B2 (en) 2009-03-20 2013-10-29 Smartcells, Inc. Soluble non-depot insulin conjugates and uses thereof
EP2408808A4 (en) 2009-03-20 2015-05-06 Smartcells Inc Terminally-functionalized conjugates and uses thereof
CA2805739A1 (en) 2010-07-28 2012-02-02 Smartcells, Inc. Drug-ligand conjugates, synthesis thereof, and intermediates thereto
AU2011282987A1 (en) 2010-07-28 2013-02-21 Smartcells, Inc. Recombinant lectins, binding-site modified lectins and uses thereof
AU2011282988A1 (en) 2010-07-28 2013-01-31 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
EP2877200B1 (en) * 2012-07-17 2019-05-08 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
US9624287B2 (en) 2012-07-17 2017-04-18 Case Western Reserve University O-linked carbohydrate-modified insulin analogues
MX360107B (en) 2012-11-13 2018-10-23 Adocia Quick-acting insulin formulation including a substituted anionic compound.
US9707276B2 (en) 2012-12-03 2017-07-18 Merck Sharp & Dohme Corp. O-glycosylated carboxy terminal portion (CTP) peptide-based insulin and insulin analogues
JP6410790B2 (en) 2013-03-14 2018-10-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Mitochondrial aldehyde dehydrogenase-2 modulator and method of use thereof
KR20160065930A (en) 2013-10-04 2016-06-09 머크 샤프 앤드 돔 코포레이션 Glucose-responsive insulin conjugates
US9795678B2 (en) 2014-05-14 2017-10-24 Adocia Fast-acting insulin composition comprising a substituted anionic compound and a polyanionic compound
FR3020947B1 (en) 2014-05-14 2018-08-31 Adocia AQUEOUS COMPOSITION COMPRISING AT LEAST ONE PROTEIN AND A SOLUBILIZING AGENT, ITS PREPARATION AND ITS USES
FR3043557B1 (en) 2015-11-16 2019-05-31 Adocia RAPID ACID COMPOSITION OF INSULIN COMPRISING A SUBSTITUTED CITRATE
CN105709207A (en) 2016-01-29 2016-06-29 徐宝贞 Medicine for treating gout
CN105597080A (en) * 2016-01-29 2016-05-25 程潜 Medicine for treating uremia and urine protein
CN105535927A (en) * 2016-01-29 2016-05-04 山东中海制药有限公司 Medicine used for treating influenza, upper respiratory infection and viral pneumonia
WO2017207754A1 (en) 2016-06-02 2017-12-07 Sanofi Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3847890A (en) * 1971-11-01 1974-11-12 A Green Acidic monosaccharide-substituted proteins
US4444683A (en) * 1982-11-17 1984-04-24 University Of Utah Glycosylated insulin derivatives
EP0119650A3 (en) * 1983-03-21 1987-09-30 THE PROCTER & GAMBLE COMPANY Galactosyl-insulin conjugates useful in treating diabetics
HU906340D0 (en) * 1986-10-13 1991-04-29 Sandoz Ag Synthesis in solid phase for producing peptonic alcohols

Also Published As

Publication number Publication date
JPH04504117A (en) 1992-07-23
GR1000604B (en) 1992-08-26
FI914226A0 (en) 1991-09-06
CN1045586A (en) 1990-09-26
CA2049937A1 (en) 1990-09-09
WO1990010645A1 (en) 1990-09-20
AU638701B2 (en) 1993-07-08
ZA901737B (en) 1990-11-28
HUT59942A (en) 1992-07-28
IL93674A0 (en) 1990-12-23
GR900100159A (en) 1990-07-31
NO913517L (en) 1991-11-06
EP0462192A1 (en) 1991-12-27
PT93366A (en) 1990-11-07
YU45490A (en) 1991-10-31
NO913517D0 (en) 1991-09-06
DD296933A5 (en) 1991-12-19
DK111489D0 (en) 1989-03-08
NZ232808A (en) 1992-04-28
AU5280790A (en) 1990-10-09
HU902787D0 (en) 1991-11-28
CS114290A3 (en) 1992-02-19

Similar Documents

Publication Publication Date Title
KR920701249A (en) Glycosylated insulin
AU543679B2 (en) Oligo saccharidic fractions and oligo saccharides having biological properties, preparation process thereof and applications thereof as medicaments
KR930002369A (en) α-glycosyl quercetin, preparation method and use thereof
FI905915A (en) TUGGUMMIKOMPOSITION.
IE781716L (en) Trihydroxypiperidine compounds
FR2688793B1 (en) COMPOSITION OF HYPOCARIOGENIC SACCHARIDES SACCHARIDES, PROCESS FOR PREPARING THE SAME AND APPLICATION THEREOF.
AU6788790A (en) Setting of gels under shear to reduce rigidity
JPS6438009A (en) Beautifying cosmetic
BR8700955A (en) MICROBICIDES PROCESS AND COMPOSITIONS TO COMBAT OR INHIBIT A CULTURE PLANT INFESTATION BY PHYTOPATHOGENIC MICROORGANISMS
EP0312127A3 (en) Glycosylated insulin derivatives
BR9502955A (en) Composition of saccharides with a reduced reducibility and processes to prepare it and to reduce the reducibility of a mixture of saccharides with a reduced reducibility
KR870007118A (en) Optically pure compound and preparation method thereof
DE3569122D1 (en) Membrane polysaccharides especially useful as medicines, and process for their preparation
KR920019263A (en) Solid containing containment ingredients, manufacturing method and use thereof
KR910004177A (en) Effervescent Formulation Composition
AU2926095A (en) Two-and three-component fungicidal mixtures
IE40957B1 (en) A 4-0- ,d glucopyransyl-2-deoxystreptamine, a process for its preparing, and compositions incorporating it
DE69002186D1 (en) CALCIUM PANTOTHENATE COMPOSITION.
IE43125L (en) Aminoglycoside derivative
JP3143269B2 (en) Hinokitiol glycoside and method for producing the same
IL43623A (en) Drug composition comprising crystallized insulin and amorphous desphenylalanine b1 insulin having antidiabetic activity
KR900018013A (en) Cyanoacetamide derivatives, preparation method thereof and plant disease control agent containing the same as an active ingredient
AU3563089A (en) New l-fucose analogs, method of preparation, application of such analogs to the preparation of new glycals, anthracyclines obtained with said glycals and utilization of said anthracyclines as drugs
KR970065726A (en) Sugar composition containing maltooligosilfuranose and maltooligosilparatinose, preparation method and use thereof
NO940304L (en) Approach   for   fermentation

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid